PubMed Health⌕ Search

Biomedical subjects

A Senra Varela

Publications and source records attributed to A Senra Varela.

At least 19 recordsLinked to original sources
PubMed2001

[Possible prognostic value of arterial hypertension in postmenopausal women with breast cancer in complete clinical remission. Pilot study].

BACKGROUND: The objective of this work was to determine the blood pressure of postmenopausal women with breast cancer in complete clinical remission of long duration. MATERIAL AND METHODS: It in a pilot study of case and controls, in which we measure the Blood Pressure (BP) of 83 postmenopausal women, with breast cancer histologically confirmed, in complete clinical remission of long duration, recruited by consecutive sampling, to compare it with that of 70 normal postmenopausal women of the same age used as controls. They ara calculated the body mass index (BMI), the corporal surface, the confidence intervals (CI) of the means, the correlation between the BMI and the BP in both groups (breast cancer patients and normal control) and between the free disease interval and the systolic and diastolic blood pressures. RESULTS: The mean of the systolic BP in 93 breast cancer patients in complete clinical remission was 163 mm Hg (95% CI 155-171) and in 70 normal controls was 134 mm Hg (95% CI 129-139). The difference between both groups in statistically significant (p < 0.001). The mean of the diastolic BP in the breast cancer patient in complete remission it was 98 mm Hg (94-104) and in the normal controls was 78 mm Hg (74-82). The difference between both groups was statistically significant (p < 0.001). CONCLUSIONS: This arterial hypertension, independent of the BMI and from the duration of the free disease interval, is associated with a long duration of the complete remission in postmenopausal breast cancer patients and consequently with a good prognostic of this disease.

Blood Pressure↗
PubMed1997

Serum ceruloplasmin as a diagnostic marker of cancer.

The pursuit of the ideal tumor marker has generated many tests for use in the diagnosis and management of cancer, several of which are now widely available. The objective of this study was to evaluate the diagnostic utility as a cancer marker of plasmatic levels of ceruloplasmin. Ceruloplasmin is a glucoprotein that transports serum copper. A case-control design was used. Serum values were evaluated in 144 patients and 103 normal controls by receiver operating characteristic (ROC) curve analysis to define the optimal cut-off levels for the serum values of ceruloplasmin in the diagnosis of cancer. The ROC analysis showed that ceruloplasmin is considerably sensitive in men (80%) at the specificity level of 80.3% and in women the sensitivity (Se) was (63.2%) and the specificity (Sp) was (63.3%). According to this study, it would seem optimal to use the cut-off level of 358 mg/l in men and 383 mg/l in women. In conclusion, serum ceruloplasmin was significantly elevated in advanced stages of solid malignant tumors, however, locally advanced or locoregionally spreading tumors did lead to significant increases (P < 0.01). Finally, the results of ROC curve analysis suggest that the ceruloplasmin is characteristic of good diagnostic markers.

Adolescent↗
PubMed1991

[Diagnosis using monoclonal antibody imaging in the clinical follow-up of colorectal cancer].

A total of 44 patients with a range of ages between 34 and 72 were studied by immunoscintigraphy. They have surgical treatment for colon and rectum carcinomas. The immunoradiotracer used was a cocktail of F(ab')2 monoclonal-antibodies anti-CEA and CA 19.9. Planar images were obtained 4th, 6th, and 10th days postinjection. In some cases we used digital subtraction of image. Both CEA and CA 19.9 tumor markers were measured in patients serum. The method shows a global high sensitivity (88%), and specificity (92%).

Adult↗
PubMed1988

A phase II trial of a new combination chemotherapy (cisplatin, bleomycin, VP-16 and methylprednisolone) in advanced recurrent squamous cell carcinoma of the head and neck.

UNLABELLED: With the aim of increasing complete responses and improving survival in advanced recurrent (after surgery and/or RXT) squamous cell carcinoma of the head and neck, we scheduled 31 patients to receive the following regimen: VP-16, 100 mg/m2 i.v. on days 1, 3 and 5; bleomycin, 10 mg/m2 i.v. on days 4, 11 and 18; cisplatin, 120 mg/m2 on day 6, and 6-methylprednisolone, 40 mg/m2 on days 1-7. Courses were repeated every 21 days. In all, 29 patients were evaluable. RESULTS: complete responses (CR) were achieved in 7 cases (24%); partial responses (PR) in 7 cases (24%); the overall response rate was 48%; stable disease in 7 cases (24%), and progressive disease in 8 cases (27.5%). In 20 cases of the N3 category there were 4 CR (20%) and 6 PR (30%). Survival: entire groups, 32.7 weeks; CR 63.8 (22+28+72+); PR, 30.2; cases of no change, 29 weeks and in nonresponders, 10 weeks. TOXICITY: leukopenia, 5/29 (17%); thrombocytopenia, 3/29 (10.3%); anemia, 10/29 (34.4%); nephrotoxicity, 8/29 (10.3%), and alopecia, reversible, 100%. CONCLUSION: this therapeutic regimen improves the CR rate and survival time with a tolerable toxicity.

Adult↗